Tag: #PharmtoExamTable

Pharm To Exam Table – Candida glabrata Urinary Tract Infections

The following is a clinical review written by Allison Graner, UNMC College of Pharmacy PharmD candidate 2019, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program What is the appropriate treatment for urinary tract infection caused by Candida glabrata? Infections caused by the fungus known as Candida, the […]

Dec 21, 2018

Pharm to Exam Table: Doravirine DRIVES the way to more ART options

The Department of Health and Human Services HIV guidelines panel currently recommends antiretroviral therapy (ART) consisting of two nucleoside reverse transcriptase inhibitors plus an integrase inhibitor for most treatment naïve HIV infected individuals1.  Prior to the advent of integrase inhibitors, the utilization of non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens had been common.   Both efavirenz […]

Oct 15, 2018

Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine

Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine Currently, triple therapy regimens constituted with a two nucleoside reverse transcriptase inhibitor backbone and anchored by an integrase inhibitor has been the standard treatment for HIV infection. However, these conventional therapies are being challenged due to their long-term side effects. Dual therapy regimens were […]

Jun 11, 2018

Pharm to Exam Table: Monoclonal Antibodies Make Their Way into HIV Treatment

Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Trogarzo® (ibalizumab-uiyk), a new monoclonal antibody treatment approved for multi-drug resistant HIV-1  On March 6th 2018, the Food and Drug Administration approved a new monoclonal antibody called ibalizumab-uiyk, marketed under the tradename Trogarzo®. Ibalizumab-uiyk (IBA) is an intravenous treatment administered every two weeks. It is intended for use […]

May 11, 2018

Pharm to Exam Table: Meet Biktarvy, the Newest of the Antiretroviral Family!

Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Biktarvy, a new co-formulated integrase inhibitor-based treatment approved for HIV On February 7th 2018, the Food and Drug Administration approved a new combination antiretroviral drug called Biktarvy®(1). Biktarvy® (B/F/TAF) is a single-tablet, once daily regimen containing the novel integrase strand transfer inhibitor bictegravir coformulated with emtricitabine and tenofovir […]

Apr 2, 2018

Pharm to Exam Table – Trimethroprim/Sulfamethoxazole for Nocardiosis

Pharm to Exam Table: Clinical Pharmacology/Antibiotic Updates – Trimethroprim/Sulfamethoxazole for Nocardiosis Nocardia is an aerobic, gram-positive bacterium commonly found in soil, decomposing vegetation, fresh water, and salt water. Nocardia is typically considered an opportunistic pathogen, but there have been several cases of nocardiosis occurring in immunocompetent hosts. Patients that are most at risk of developing nocardiosis are those with […]

Feb 26, 2018